AU2019338032A1 — Salts of substituted pyrrolopyrimidine CDK inhibitor, crystal and use thereof
Assigned to Chia Tai Tianqing Pharmaceutical Group Co Ltd · Expires 2021-05-20 · 5y expired
What this patent protects
The present application belongs to the field of pharmaceutical chemistry and relates to salts of a substituted pyrrolopyrimidine CDK inhibitor, and particularly relates to a compound, 7-cyclopentyl-6-N,N-dimethylaminoformyl-N-(5-(1,2,3,6-4H-pyridine-4-yl)pyridine-2-yl)-7H-pyrrolo…
USPTO Abstract
The present application belongs to the field of pharmaceutical chemistry and relates to salts of a substituted pyrrolopyrimidine CDK inhibitor, and particularly relates to a compound, 7-cyclopentyl-6-N,N-dimethylaminoformyl-N-(5-(1,2,3,6-4H-pyridine-4-yl)pyridine-2-yl)-7H-pyrrolo[2,3-d]pyrimidine-2-amine maleate (as represented by formula II), a crystal form of the compound represented by formula II, a preparation method therefor, and a pharmaceutical composition. The present application also relates to a use of the salts of the compound and the pharmaceutical composition thereof in preparing a drug for treating diseases related to the inhibitory effects of CDK4 and/or CDK6.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.